FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994411312> ?p ?o ?g. }

• W1994411312 endingPage "391" @default.
• W1994411312 startingPage "387" @default.
• W1994411312 abstract "Summary. The response to hepatitis C virus (HCV) therapy seems to be lower in HCV/HIV‐coinfected patients than in HCV‐monoinfected individuals. Given that most pivotal trials conducted in coinfected patients have used the combination of pegylated interferon (pegIFN) along with fixed low doses (800 mg/day) of ribavirin (RBV), it is unclear whether HIV itself and/or suboptimal RBV exposure could explain this poorer outcome. Two well‐defined end points of early virological response were evaluated in Peginterferon Ribavirina España Coinfección (PRESCO), a multicentre trial in which the combination of pegIFN plus RBV (1000 mg if body weight <75 kg and 1200 mg if >75 kg) was prescribed to coinfected patients. For comparisons, we used unpublished data from early kinetics in two other large trials, one performed in HIV‐negative patients [Pegasys International Study Group (PISG)] in which RBV 1000–1200 mg/day was used and another [AIDS Pegasys Ribavirin Coinfection Trial (APRICOT)] in which HIV‐positive patients received fixed low RBV doses (800 mg/day). A total of 348 HCV/HIV‐coinfected patients from the PRESCO trial were analysed as well as all patients treated with pegIFN plus RBV, who completed 12 weeks of therapy in the comparative studies (435 in PISG and 268 in APRICOT). Negative serum HCV‐RNA at week 4 (which has the highest positive predictive value of sustained virological response, SVR) was attained in 33.3%, 31.2% and 13% of treated patients with HCV genotype 1, respectively, in PRESCO, PISG and APRICOT. For HCV genotypes 2/3, responses were 83.7%, 84.2% and 37%, respectively. A decline lower than 2 log 10 at week 12 (which has the highest negative predictive value of SVR) was seen in 25.5%, 19.5% and 37% of HCV genotype‐1‐infected patients, and in 2.1%, 2.9% and 12% of genotypes‐2/3‐infected patients, respectively. Prescription of high RBV doses enhances the early virological response to HCV therapy in HCV/HIV‐coinfected patients, with results approaching those seen in HCV‐monoinfected patients." @default.
• W1994411312 created "2016-06-24" @default.
• W1994411312 creator A5003553956 @default.
• W1994411312 creator A5009751300 @default.
• W1994411312 creator A5015434274 @default.
• W1994411312 creator A5019841865 @default.
• W1994411312 creator A5023090633 @default.
• W1994411312 creator A5025958254 @default.
• W1994411312 creator A5028478010 @default.
• W1994411312 creator A5030580762 @default.
• W1994411312 creator A5058909267 @default.
• W1994411312 creator A5065664764 @default.
• W1994411312 creator A5072006119 @default.
• W1994411312 creator A5075118902 @default.
• W1994411312 creator A5083352060 @default.
• W1994411312 creator A5084131412 @default.
• W1994411312 creator A5085763339 @default.
• W1994411312 creator A5087702556 @default.
• W1994411312 date "2006-10-24" @default.
• W1994411312 modified "2023-10-12" @default.
• W1994411312 title "Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients" @default.
• W1994411312 cites W1967080996 @default.
• W1994411312 cites W1970053808 @default.
• W1994411312 cites W1976396315 @default.
• W1994411312 cites W1986283951 @default.
• W1994411312 cites W1992239172 @default.
• W1994411312 cites W1996434966 @default.
• W1994411312 cites W2004602615 @default.
• W1994411312 cites W2005933189 @default.
• W1994411312 cites W2007062588 @default.
• W1994411312 cites W2007209701 @default.
• W1994411312 cites W2007921510 @default.
• W1994411312 cites W2027545702 @default.
• W1994411312 cites W2031780296 @default.
• W1994411312 cites W2061294380 @default.
• W1994411312 cites W2078717093 @default.
• W1994411312 cites W2094883696 @default.
• W1994411312 cites W2102371310 @default.
• W1994411312 cites W2103529803 @default.
• W1994411312 cites W2111790487 @default.
• W1994411312 cites W2121595515 @default.
• W1994411312 cites W2122764811 @default.
• W1994411312 cites W2127685726 @default.
• W1994411312 cites W2142746239 @default.
• W1994411312 cites W2151020178 @default.
• W1994411312 cites W2160997908 @default.
• W1994411312 cites W2162099143 @default.
• W1994411312 cites W2171689172 @default.
• W1994411312 cites W2404044846 @default.
• W1994411312 cites W248249256 @default.
• W1994411312 cites W4251925572 @default.
• W1994411312 doi "https://doi.org/10.1111/j.1365-2893.2006.00806.x" @default.
• W1994411312 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17501758" @default.
• W1994411312 hasPublicationYear "2006" @default.
• W1994411312 type Work @default.
• W1994411312 sameAs 1994411312 @default.
• W1994411312 citedByCount "38" @default.
• W1994411312 countsByYear W19944113122012 @default.
• W1994411312 countsByYear W19944113122013 @default.
• W1994411312 countsByYear W19944113122014 @default.
• W1994411312 countsByYear W19944113122015 @default.
• W1994411312 crossrefType "journal-article" @default.
• W1994411312 hasAuthorship W1994411312A5003553956 @default.
• W1994411312 hasAuthorship W1994411312A5009751300 @default.
• W1994411312 hasAuthorship W1994411312A5015434274 @default.
• W1994411312 hasAuthorship W1994411312A5019841865 @default.
• W1994411312 hasAuthorship W1994411312A5023090633 @default.
• W1994411312 hasAuthorship W1994411312A5025958254 @default.
• W1994411312 hasAuthorship W1994411312A5028478010 @default.
• W1994411312 hasAuthorship W1994411312A5030580762 @default.
• W1994411312 hasAuthorship W1994411312A5058909267 @default.
• W1994411312 hasAuthorship W1994411312A5065664764 @default.
• W1994411312 hasAuthorship W1994411312A5072006119 @default.
• W1994411312 hasAuthorship W1994411312A5075118902 @default.
• W1994411312 hasAuthorship W1994411312A5083352060 @default.
• W1994411312 hasAuthorship W1994411312A5084131412 @default.
• W1994411312 hasAuthorship W1994411312A5085763339 @default.
• W1994411312 hasAuthorship W1994411312A5087702556 @default.
• W1994411312 hasConcept C126322002 @default.
• W1994411312 hasConcept C142462285 @default.
• W1994411312 hasConcept C203014093 @default.
• W1994411312 hasConcept C2522874641 @default.
• W1994411312 hasConcept C2776408679 @default.
• W1994411312 hasConcept C2776455275 @default.
• W1994411312 hasConcept C2776461080 @default.
• W1994411312 hasConcept C2777813720 @default.
• W1994411312 hasConcept C2780040827 @default.
• W1994411312 hasConcept C3013748606 @default.
• W1994411312 hasConcept C71924100 @default.
• W1994411312 hasConcept C90924648 @default.
• W1994411312 hasConceptScore W1994411312C126322002 @default.
• W1994411312 hasConceptScore W1994411312C142462285 @default.
• W1994411312 hasConceptScore W1994411312C203014093 @default.
• W1994411312 hasConceptScore W1994411312C2522874641 @default.
• W1994411312 hasConceptScore W1994411312C2776408679 @default.
• W1994411312 hasConceptScore W1994411312C2776455275 @default.
• W1994411312 hasConceptScore W1994411312C2776461080 @default.
• W1994411312 hasConceptScore W1994411312C2777813720 @default.

• next